XBiotech Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $37,757 | $32,848 |
| General and administrative | 4,714 | 4,662 |
| Total operating expenses | 42,471 | 37,510 |
| Loss from operations | (42,471) | (37,510) |
| Other income (expense): | ||
| Interest income | 9,812 | 10,421 |
| Interest expense | (807) | - |
| Other income | 432 | 883 |
| Foreign exchange (loss) gain | (5,529) | 1,893 |
| Total other income | 3,908 | 13,197 |
| Loss before income taxes | (38,563) | (24,313) |
| Income tax benefit (expense) | 32 | (244) |
| Net loss | $(38,531) | $(24,557) |
| Net loss per share—basic and diluted | $(1.26) | $(0.81) |
| Shares used to compute basic and diluted net loss per share | 30,460,980 | 30,438,459 |
See accompanying notes to consolidated financial statements.
Consolidated Statements of Comprehensive Loss
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.